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1. Introduction  
Phenolic acids coupled with amino acids or amines can 
be obtained from natural sources or synthetically. It is 
assumed that these bioactive substances are involved in 
suppression of deleterious effects of oxidative stress and 
have a wide range of biological activities such as 
antioxidant,1-5 anticancer6 and antimicrobial.7-12 In fact, the 
accumulation of hydroxycinnamic acid amides constitutes 
part of the defence system of plants that is activated as 
response to various environmental stimuli such as 
wounding, fungal infection or heavy metal ions.13-16 Lee et 
al. prepared a series of cinnamic acid derivatives and 
evaluated their biological activities in lipoprotein 
metabolism.17 The methyl esters of N-(4-
hydroxycinnamoyl)-L-phenylalanine and the dibenzyl ester 
of N-caffeoyl-aspartic acid showed potent anti-atherogenic 
and antioxidant activities. Moreover, amides of cinnamic, 
ferulic and sinapic acids with natural and unnatural C-
protected amino acids have been synthesized and also 
showed antimicrobial activity, radical scavenging activity 
against the free 2,2-diphenyl-1-picrylhydrazyl radical and 
antioxidant activity in bulk oil.18-19 
Several studies suggest that a cocktail of antioxidants, 
endowed with different molecular structures and 
mechanisms of action, result more effective than a single 
antioxidant, due to the synergic effect between different 
types of molecules.20-26 To highlight possible synergic 
mechanisms and to better understand mechanistic aspects, 
the design of modified and/or dualistic molecules is a 
valuable approach. Studies have confirmed that conjugation 
between different types of compounds such as amino acids 
with phenolic acids is useful, not only to investigate 
structure-activity relationships, but can also constitute a 
strategy to improve antioxidant efficiency and bioactivity.27-
29 
Another application of phenolic or catecholic amino 
acids is in the design of new peptide hydrogels that mimic 
mussel adhesive proteins.30 The extraordinary ability of 
mussel adhesive proteins is mainly attributed to the 
reversible metal-catechol coordination between metals like 
Fe3+and catechol groups from the amino acid 3,4-
dihydroxyphenyl-L-alanine (DOPA), and also to other 
interactions such as cation- interactions.31 Recently, a new 
type of injectable hydrogel based on self-assembly of an 
ABA tri-block copolymer with rapid self-healing properties 
through mussel-inspired catechol-mediated hydrogen 
bonding interactions and aromatic interactions and with anti-
biofouling capability was described.32 
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Non-coded amino acids can have a variety of 
applications such as in structure-activity relationship studies, 
as antiviral, antitumor, anti-inflammatory or 
immunosuppressor compounds or in the development of 
new biomaterials.33-35  In particular, dehydroamino acids 
constitute an important class of non-proteinogenic amino 
acids with various biological activities including 
antioxidant.36-48 In general, the presence of one or more α,β-
dehydroamino acid in a polypeptide chain has strong impact, 
not only on the secondary structure  adopted, but also on 
their biological behaviour, including antibacterial, antifungal 
and antitumor activities36-38 and resistance to proteolysis.  
Recently, several low molecular weight dehydrodipeptide 
hydrogelators were prepared and studied as new drug 
delivery systems.49,50  Thus, the combination of phenolic or 
catecholic moieties with dehydroamino acids can be a 
valuable approach to the development of new biologically 
active compounds. 
In our laboratories we developed an efficient method for 
the synthesis of N,N-diacyl-α,β-dehydroamino acid 
derivatives by using two equivalents of tert-
butyldicarbonate (Boc2O) and 4-dimethylaminopyridine 
(DMAP) as catalyst in dry acetonitrile.51  In order to allow 
the synthesis of N-monoprotected dehydroamino acid 
derivatives, a modification of this method was subsequently 
reported.52 Thus, by reacting β-hydroxyamino acid 
derivatives with one equivalent of Boc2O and DMAP it was 
possible to obtain the corresponding β-carbonates that 
undergo β-elimination by treatment with N,N,N’,N’-
tetramethylguanidine (TMG).  
In this work and in order to explore the effect of 
combining a dehydroamino acid moiety with phenolic or 
catecholic acids, an innovative strategy for the synthesis of 
these conjugates was developed. This new methodology 
involves the simultaneous tert-butyloxycarbonylation of all 
hydroxyl groups present in the N-protected -hydroxyamino 
acids followed by a selective -elimination reaction and 
cleavage of the aromatic O-tert-butyloxycarbonyl groups. 
The non-coded amino acids prepared can have biological 
activity or can be use in the design of new peptide hydrogels 
that mimic mussel adhesive proteins.  
 
2. Results and Discussion   
The methyl ester of N-(4-hydroxybenzoyl) dehydroalanine 
was prepared from 4-hydroxybenzoic acid (a) and the 
methyl ester of serine (1). The coupling between a and 1 
was carried out using 2-(1H-benzotriazol-1-yl)-1,1,3,3-
tetramethyluronium hexaﬂuorophosphate (HBTU) and 1-
hydroxybenzotriazole (HOBt) to give the methyl ester of N-
(4-hydroxybenzoyl)serine in 71% yield (Scheme 1, 
compound 1a). This compound was treated with two 
equivalents of Boc2O and DMAP as catalyst in acetonitrile 
to afford compound 2a (Scheme 1). In the proton NMR 
spectrum of this compound it is possible to observe two 
singlets at 1.47 ppm and 1.57 ppm that correspond to the 
protons of the two tert-butyloxycarbonyl (Boc) groups. 
Compound 2a was reacted with a solution of TMG in 
acetonitrile to give the dehydroalanine derivative 3a in 31% 
yield (Scheme 1). The proton NMR spectrum of 3a shows 
two singlets at 6.01 ppm and 6.79 ppm caracteristic of the β-
CH2 protons of dehydroalanine. Cleavage of the aromatic O-
Boc group from 3a was accomplished using trifluoroacetic 
acid, giving compound 4a in 47% yield (Scheme 1).  
Scheme 1. Synthesis of the methyl ester of N-(4-hydroxybenzoyl) 
dehydroalanine. 
 
In order to improve the low overall yield, a one-pot 
procedure was tested. Thus, compound 1a was used in a 
sequential reaction with Boc2O/DMAP, followed by TMG 
and finally TFA. Compound 4a was isolated in 47% yield 
(Scheme 2, Table 1).  
The same methodology was applied with the methyl 
ester of serine and other phenolic and catecholic acids to 
give the dehydroalanine derivatives 4c, 4e and 4f (Scheme 
2, Table 1). Although attempted, it was impossible to isolate 
the coupling products between serine and protocatechuic 
acid (b), 2-(3,4-dihydroxyphenyl) acetic acid (d), 
hydrocaffeic acid (g) and gallic acid (h). This may be due to 
the high hydrophilic character of compounds 1b, 1d, 1g and 
1h when compared with the other serine derivatives 
(compounds 1a, 1c, 1e and 1f). 
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Scheme 2. One-pot procedure used in the synthesis of the methyl esters of N-phenoyl and N-catechoyl dehydroalanine. 
 
Table 1 
Yields obtained in the synthesis of the methyl esters of N-phenoyl and N-catechoyl serine and in the 
synthesis of the corresponding dehydroalanine derivatives using a one-pot procedure.  
Phenolic or catecholic serine  
derivative  
Yield 
(%) 
Phenolic or catecholic dehydroalanine 
derivative 
Yield 
(%) 
4-Hydroxybenzoyl-L-Ser-OMe, 1a 71 4-Hydroxybenzoyl-Ala-OMe, 4ª 47 
2-(4-Hydroxyphenyl)acetoyl-L-Ser-OMe, 1c 52 2-(4-Hydroxyphenyl)acetoyl-Ala-OMe, 4c 36 
p-Coumaroyl-L-Ser-OMe, 1e 57 p-Coumaroyl-Ala-OMe, 4e 68 
Caffeoyl-L-Ser-OMe, 1f 71 Caffeoyl-Ala-OMe, 4f 26 
 
The same approach was applied to the synthesis of 
dehydrophenylalanine derivatives N-capped with 
phenolic or catecholic acids. Thus, the methyl ester of N-
caffeoylphenylserine was prepared by coupling caffeic 
acid (f) with the methyl ester of phenylserine (5) to give 
compound 5f (Scheme 3). Compound 5f was treated with 
three equivalents of Boc2O and DMAP to give compound 
6f. The three singlets corresponding to the 27 protons of 
the three Boc groups were observed in the proton NMR 
spectrum at 1.47, 1.56 and 1.57 ppm. Compound 6f was 
reacted with TMG to give dehydrophenylalanine 7f which 
gave 8f after cleavage of the aromatic O-Boc groups. The 
dehydrophenylalanine derivative was obtained in 29% 
overall yield (Scheme 3). 
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Scheme 3. Synthesis of the methyl ester of N-
caffeoyldehydrophenyl-alanine. 
 
As observed for the dehydroalanine derivatives the 
overall yield in compound 5f was considerably improved 
using the one-pot procedure (Scheme 4, Table 2). Thus, 
all other phenolic and catecholic acids (a-e, g, h) were 
reacted with the methyl ester of phenylserine. The lower 
hidrophylicity of the phenylserine derivatives obtained, 
allowed the preparation of all N-protected phenylserine 
derivatives in good yields (Scheme 4, Table 2, 
compounds 5a-e, 5g, 5h). The one-pot procedure was 
carried out with all N-protected phenylserine derivatives 
to give the Z-isomer of the corresponding 
dehydrophenylalanine derivative (Scheme 4, Table 2, 
compounds 8a-e, 8g). The stereochemistry of the 
dehydrophenylalanine moieties was confirmed using 
NOE difference experiments by irradiating the OMe 
protons and observing an NOE enhancement on the signal 
of the -CH proton. The N-galloyl phenylserine 
derivative (compound 5h) was treated in the same 
conditions but the only product isolated was N-
deprotected dehydrophenylalanine (H-Z-Phe-OMe). 
This probably resulted from the higher nucleophilic 
character of the amide nitrogen of the galloyl derivative, 
which led to the preferential tert-butyloxycarbonylation 
of the amide, making the galloyl group susceptible to 
cleavage by TMG. This was described by Ragnarsson and 
co-workers for cleavage of acyl groups from N-acyl-N-
Boc-amines.54 The subsequent treatment with TFA of the 
N-tert-butyloxycarbonyl dehydrophenylalanine formed 
led to the methyl ester of dehydrophenylalanine.  
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Scheme 4. One-pot procedure used in the synthesis of the methyl esters of N-phenoyl and N-catechoyl 
dehydrophenylalanine. 
 
Table 2 
Yields obtained in the synthesis of the methyl esters of N-phenoyl and N-catechoyl phenylserine and in the synthesis of the 
corresponding dehydrophenylalanine derivatives using a one-pot procedure.  
Phenolic or catecholic phenylserine  
derivative  
Yield 
(%) 
Phenolic or catecholic dehydrophenylalanine 
derivative 
Yield 
(%) 
4-Hydroxybenzoyl-D,L-Phe(-OH)-OMe, 5a 96 4-Hydroxybenzoyl-Z-Phe-OMe, 8a 57 
Protocatechoyl-D,L-Phe(-OH)-OMe, 5b 86 Protocatechoyl-Z-Phe-OMe, 8b 21 
2-(4-Hydroxyphenyl)acetoyl-D,L-Phe(-OH)-OMe, 5c 89 2-(4-Hydroxyphenyl)acetoyl-Z-Phe-OMe, 8c 63 
2-(3,4-diHydroxyphenyl)acetoyl-D,L-Phe(-OH)-OMe, 5d 86 2-(3,4-diHydroxyphenyl)acetoyl-Z-Phe-OMe, 8d 43 
p-Coumaroyl-D,L-Phe(-OH)-OMe, 5e 80 p-Coumaroyl-Z-Phe-OMe, 8e 60 
Caffeoyl-D,L-Phe(-OH)-OMe, 5f 97 Caffeoyl-Z-Phe-OMe, 8f 55 
Hydrocaffeoyl-D,L-Phe(-OH)-OMe, 5g 89 Hydrocaffeoyl-Z-Phe-OMe, 8g 52 
Galloyl-D,L-Phe(-OH)-OMe, 5h 76 Galloyl-Z-Phe-OMe, 8h -- 
 
The preparation of C-deprotected dehydroalanine and 
dehydrophenylalanine derivatives requires the removal of 
the methyl esters. However, due to the relative ease with 
which catechol groups oxidize, are prone to nucleophilic 
attack and phenolic coupling reactions in basic media, it is 
not possible to remove the methyl esters from compounds 
4a, 4c, 4e, 4f and 8a-g. Alternatively, the C-deprotected 
N-catechoyl dehydroamino acid derivatives were prepared 
by a sequential tert-butyloxycarbonylation and 
dehydration; followed by treatment with base to remove 
the methyl ester and cleavage of the Boc groups with 
TFA. Compound 5b was reacted with Boc2O/DMAP 
followed by TMG to give the O-(tert-
butyloxycarbonylated) dehydrophenylalanine derivative 
7b (Scheme 5). Treatment of this compound  with an 
aqueous solution of NaOH in dioxane, followed by TFA 
gave the C-deprotected N-catechoyl dehydrophenylalanine 
derivative (compound 9b).  
 
Scheme 5. Two-step procedure to prepare C-deprotected N- 
protocatechoyl dehydrophenylalanine. 
 
Compounds 5e-g were also used as substrates in the 
same two-step procedure to give the corresponding N-
phenoyl or N-catechoyl dehydrophenylalanine 
derivatives 9e-g (Scheme 6). 
 
 
Scheme 6. C-deprotected N-phenoyl or catechoyl 
dehydrophenyl-alanines. 
 
Several alanine derivatives were also prepared by 
coupling phenolic and catecholic acids with the methyl 
ester of alanine (scheme 7). Some of these compounds 
were used as standards in the preliminary biological 
assays described below and all will be used as standards 
in future screening tests. 
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Scheme 7.  Methyl esters of N-phenoyl and catechoyl alanine. 
 
The toxicity of the alanine, dehydroalanine and 
dehydrophenylalanine derivatives was evaluated against 
a panel of human cancer [gastric cancer (AGS), lung 
cancer (A549)] and non-cancer [lung fibroblasts (MRC-
5)] cell lines. All molecules were tested in a 
concentration range up to 25 μM after 24 h of incubation 
(Figure 1). 
 
Fig. 1. Effect of the alanine, dehydroalanine and 
dehydrophenylalanine derivatives in the viability of AGS cells 
(human gastric cancer), A549 cells (human non-small lung 
cancer) and MRC-5 cells (human lung) after 24 hours. 
Statistical significance: *p < 0.05, **p < 0.01, ***p < 0.001. 
Results presented as mean ± standard deviation of the mean. 
In the case of AGS cancer cells, compounds 10e, 10f, 
4e and 4f where devoid of significant toxicity (Figure 1). 
The introduction of an aryl group in compounds 8e and 
8f, exerted some limited toxicity at the highest 
concentrations tested. For example, 8e caused loss of 
viability around 20% at 12.5 μM, with 8f exhibiting the 
same effect at 25 μM. The higher toxicity for compound 
8e and 8f may be attributed to their higher liposolubility. 
In the case of the A549 cell line, which is characterized 
as a highly aggressive phenotype with high resistance to 
chemotherapeutic drugs,55 the alanine, dehydroalanine 
and dehydrophenylalanine derivatives were either not 
toxic or caused only minor changes in viability.  Results 
for the non-cancer cell line MRC-5 show that, in general, 
molecules displayed no toxicity in the concentration 
range tested. 
  
3. Conclusions 
A new synthetic strategy based on the tert-
butyloxycarbonylation of hydroxyl groups present in 
serine and phenylserine derivatives N-acylated with 
phenolic and catecholic acids allowed the preparation of 
a wide range of N-phenolic and N-catecholic 
dehydroalanines and dehydrophenylalanines in moderate 
yields. The yields were considerably improved using this 
methodology in a one-pot procedure. C-Deprotected 
dehydroamino derivatives were also prepared in a two-
step process: the first step comprising sequential tert-
butyloxycarbonylation and dehydration; followed by a 
sequential methyl ester cleavage with base and removal 
of the tert-butyloxycarbonyl groups with TFA.  
These novel compounds can have important biological 
activities resulting from the synergic effects of both the 
catechol and the dehydro moieties. Preliminary assays on 
the toxicity of representative compounds towards two 
human cancer cell lines show that the most potent 
molecules were the dehydrophenylalanine derivatives, 
which can be attributed to their higher liposolubility. 
Assays of these compounds on cell viability against a 
non-cancer cell line showed that the molecules display 
very low or no toxicity in the concentration range tested 
(up to 25 μM). Thus, the toxicity of the molecules was 
higher towards cancer cells than non-cancer cells. These 
results show the impact of the chemical structure upon 
potency and tropism towards cancer cells. This 
information will be useful for further modification of 
these molecules, aiming to increase their bioactivity. 
They also indicate that these molecules are excellent 
candidates for incorporation into peptide-based 
hydrogels with potential in various bioengineering 
applications such as drug delivery. 
  
4. Experimental Section 
4.1. General methods 
 Melting points (ºC) were determined in a 
Gallenkamp apparatus and are uncorrected. 1H and 13C 
NMR spectra were recorded on a Bruker Avance II+ at 
400 and 100.6 MHz, respectively. 1H-1H spin-spin 
decoupling, DEPT  45º, HMQC and HMBC were used 
to attribute some signals. Chemical shifts are given in 
ppm and coupling constants in Hz. HRMS data were 
recorded by the Laboratory for Structural Elucidation of 
the Materials Centre of the University of Porto on an 
LTQ OrbitrapTM XL hybrid mass spectrometer (Thermo 
Fischer Scientific, Bremen, Germany) controlled by LTQ 
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Tune Plus 2.5.5 and Xcalibur 2.1.0. The reactions were 
monitored by thin layer chromatography (TLC). Column 
chromatography was performed on Macherey-Nagel 
silica gel 230-400 mesh. Petroleum ether refers to the 
boiling range 40-60 ºC. Solvents were used without 
purification except for acetonitrile which was dried using 
standard procedures.  
4.1.1. Cell culture. Human gastric carcinoma cell line 
AGS and human lung carninoma cell line A549 were 
from Sigma-Aldrich, St. Louis, MO, USA, and human 
lung fibroblast cell line MRC-5 was from ECACC, 
Porton Down Salisbury, UK. Cells were cultured as 
monolayer at 37 °C in a humidified incubator with 5% 
carbon dioxide. AGS were grown in glutamine-enriched 
Dulbecco's Modified Eagle Medium (DMEM), 
supplemented with 1% streptomycin/penicillin and 10% 
fetal bovine serum (Gibco®), while A549 and MRC-5 
cells were grown in DMEM/F-12, supplemented with 
1% streptomycin/ penicillin and 10% fetal bovine serum. 
For subculture, cells were washed with Hank’s buffered 
salt solution (HBSS), treated with 0.25% Trypsin-EDTA 
solution (Sigma, St. Louis, MO) for 3 min at 37 °C, 
resuspended in 5 mL of culture medium and centrifuged 
at 390 g for 4 min. The supernatant was removed and the 
cell pellet was resuspended in culture medium.  
4.1.2.Cell viability. The MTT assay was conducted as 
described before.53 Cells were plated at a density of 
1,5x104 cells/well for AGS, 1x104 cells/well for A549 
and 2.5x104 cells/well for MRC-5 and allowed to attach 
for 24 hours. Cells were exposed to the molecules under 
study in a concentration n range up to 25 μM range, for 
24 hours. After this period, the medium was replaced by 
100 µL of 0.5 mg/mL MTT solution and incubated for 2 
hours. The formazan in each well was then dissolved in 
200 µL of a solution of 3:1 DMSO:isopropanol. Finally, 
the absorbance at 560 nm was read in a Thermo 
Scientific™ Multiskan™ GO microplate reader. 
All determinations were performed in duplicate and the 
results were confirmed in three independent assays. 
 
4.2. Synthesis 
4.2.1. Synthesis of the methyl esters of N-phenoyl and N-
catechoyl serine, phenylserine and alanine  
General procedure for the synthesis of the methyl esters 
of N-phenoyl and N-catechoyl serine, phenylserine and 
alanine 
To a solution of the phenolic or catecholic 
acid in acetonitrile (0.0100 mol dm-3), 1.1 equiv. 
of HOBt was added, followed by 1.1 equiv. of HBTU, 
1.1 equiv. of the methyl ester of the amino acid 
hydrochloride and 2.2 equiv. of NEt3 in an ice bath. After 
stirring for 4 hours at room temperature, the solvent was 
evaporated at reduced pressure. The residue was 
dissolved in ethyl acetate (100 cm3) and washed with 
KHSO4 (1 mol dm-3), NaHCO3 (1 mol dm-3) and brine (3 
times 25 cm3 each). The organic layer was dried with 
MgSO4 and the solvent evaporated at reduced pressure.  
4.2.1.1. Synthesis of 4-hydroxybenzoyl-L-Ser-OMe, (1a) 
The general procedure described above was followed 
with 4-hydroxybenzoic acid (0.345 g, 2.500 mmol) and 
HCl.H-L-Ser-OMe to give compound 1a (0.425 g, 
71.0%) as a colourless oil. 1H NMR (400 MHz, 
CD3OCD3): δ = 3.74 (s, 3H, COOCH3), 3.95 (dd, J = 4.4 
Hz, J = 11.2 Hz, 1H, CH2), 4.02 (dd, J = 4.4 Hz, J = 
11.2 Hz, 1H, CH2), 4.73-4.77 (m, 1H, CH), 6.93 (d, J 
= 8.8 Hz, 2H, ArH), 7.59 (br. d, J = 7.6 Hz, 1H, NH), 
7.85 (d, J = 8.8 Hz, 2H, ArH), 9.01 (br. s, 1H, OH) 
ppm. 13C NMR (100.6 MHz, CD3OCD3): δ = 52.30 
(CO2CH3), 56.13 (CH), 62.90 (CH2), 115.74 (2CH), 
126.26 (C), 130.13 (2CH), 161.29 (C), 167.07 (C=O), 
171.92 (C=O) ppm. m/z (HRESI-MS) 240.08674, ([M + 
H]+, C11H14NO5, requires 240.08720). 
4.2.1.2. Synthesis of 2-(4-hydroxyphenyl)acetoyl-L-Ser-
OMe, (1c) The general procedure described above was 
followed with 2-(4-hydroxyphenyl)acetic acid (0.380 g, 
2.500 mmol) and  HCl.H-L-Ser-OMe to give compound 
1c (0.330 g, 52.2%) as a colourless oil that solidified on 
standing. M.p. 64.0-65.0 °C. 1H NMR (400 MHz, 
CD3OCD3): δ = 3.53 (s, 2H, CH2), 3.69 (s, 3H, 
COOCH3), 3.78 (dd, J = 4.0 Hz, J = 11.2 Hz, 1H, CH2), 
3.92 (dd, J = 4.0 Hz, J = 11.2 Hz, 1H, CH2), 4.25 (br. s, 
1H, OH Ser), 4.52-4.57 (m, 1H, CH), 6.80 (d, J = 8.8 
Hz, 2H, ArH), 7.19 (d, J = 8.8 Hz, 2H, ArH), 7.25 (br. s, 
1H, OH), 8.30 (br. s, 1H, NH) ppm. 13C NMR (100.6 
MHz, CD3OCD3): δ = 42.48 (CH2), 52.25 (CO2CH3), 
55.54 (CH), 62.83 (CH2), 115.93 (CH), 122.25 (CH), 
127.44 (C), 131.12 (2CH), 156.99 (C), 171.69 (C=O), 
171.76 (C=O) ppm. m/z (HRESI-MS) 254.10235, ([M + 
H]+, C12H16NO5, requires 254.10285). 
4.2.1.3. Synthesis of p-coumaroyl-L-Ser-OMe, (1e) The 
general procedure described above was followed with p-
coumaric acid (0.410 g, 2.500 mmol) and HCl.H-L-Ser-
OMe to give compound 1e (0.374 g, 56.6%) as a light 
yellow oil. 1H NMR (400 MHz, CD3OCD3): δ = 3.73 (s, 
3H, COOCH3), 3.87 (dd, J = 4.0 Hz, J = 11.2 Hz, 1H, 
CH2), 3.98 (dd, J = 4.0 Hz, J = 11.2 Hz, 1H, CH2), 
4.70 (t, J = 4.0 Hz, 1H, CH), 6.73 (d, J = 15.6 Hz, 1H, 
Ar-CH=CH-), 6.90 (d, J = 8.8 Hz, 2H, ArH), 7.48-7.54 
(m, 3H, ArH + Ar-CH=CH-) ppm. 13C NMR (100.6 
MHz, CD3OCD3): δ = 52.27 (CO2CH3), 55.63 (CH), 
63.05 (CH2), 116.49 (2CH), 119.03 (CH), 127.67 (C), 
130.26 (2CH), 140.96 (CH), 159.74 (C), 166.38 (C=O), 
171.83 (C=O) ppm. m/z (HRESI-MS) 266.10202, ([M + 
H]+, C13H16NO5, requires 266.10285). 
4.2.1.4. Synthesis of caffeoyl-L-Ser-OMe, (1f) The 
general procedure described above was followed with 
caffeic acid (0.450 g, 2.500 mmol) and  HCl.H-L-Ser-
OMe to give compound 1f (0.495 g, 70.5%) as a 
colourless oil. 1H NMR (400 MHz, CD3OCD3): δ = 3.73 
(s, 3H, COOCH3), 3.88 (dd, J = 4.0 Hz, J = 10.8 Hz, 1H, 
CH), 3.99 (dd, J = 4.0 Hz, J = 10.8 Hz, 1H, CH), 4.70-
4.74 (m, 1H, CH), 6.69 (d, J = 15.6 Hz, 1H, Ar-
CH=CH-), 6.85-6.88 (m, 1H, ArH), 6.94-7.00 (m, 1H, 
ArH), 7.13 (d, J = 2.0 Hz, 1H, ArH), 7.47 (d, J = 15.6 
Hz, 1H, Ar-CH=CH-), 8.37 (br. s, 1H, NH) ppm. 13C 
NMR (100.6 MHz, CD3OCD3): δ = 52.32 (CO2CH3), 
55.64 (CH), 63.06 (CH2), 114.84 (CH), 116.26 (CH), 
118.92 (CH), 118.97 (CH), 121.77 (CH), 128.26 (C), 
141.52 (CH), 146.13 (C), 147.87 (C), 166.69 (C=O), 
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171.79 (C=O) ppm. m/z (HRESI-MS) 282.09683, ([M + 
H]+, C13H16NO6, requires 282.09776). 
4.2.1.5. Synthesis of 4-hydroxybenzoyl-D,L-Phe(-OH)-
OMe, (5a) The general procedure described above was 
followed with 4-hydroxybenzoic acid (0.345 g, 
2.500 mmol) and HCl.H-D,L-Phe(-OH)-OMe to give 
compound 5a (0.758 g, 96.2%) as a colourless oil. 1H 
NMR (400 MHz, CD3OCD3): δ = 3.72 (s, 3H, 
COOCH3), 4.96 (dd, J = 3.6 Hz, J = 8.8 Hz, 1H, CH), 
5.22 (br. s, 1H, OH), 5.42 (br. s, 1H, CH), 6.89 (d, J = 
8.8 Hz, 2H, ArH), 7.24-7.36 (m, 3H, ArH), 7.51 (d, J = 
8.4 Hz, 2H, ArH), 7.75 (d, J = 8.8 Hz, 2H, ArH), 8.96 
(br. s, 1H, NH) ppm. 13C NMR (100.6 MHz, CD3OCD3): 
δ = 52.37 (CO2CH3), 59.98 (CH), 73.80 (CH), 115.78 
(CH), 126.21 (C), 126.87 (2CH), 128.16 (CH), 128.81 
(2CH), 130.04 (2CH), 134.10 (CH), 142.47 (C), 161.33 
(C), 167.29 (C=O), 171.65 (C=O) ppm. m/z (HRESI-
MS) 316.11787, ([M + H]+, C17H18NO5, requires 
316.11850). 
4.2.1.6. Synthesis of protocatechoyl-D,L-Phe(-OH)-
OMe, (5b) The general procedure described above was 
followed with protocatechuic acid (0.385 g, 2.500 mmol) 
and HCl.H-D,L-Phe(-OH)-OMe to give compound 5b 
(0.712 g, 86.0%) as a white solid. (from ethyl 
acetate/petroleum ether). M.p. 164.0-165.0 °C. 1H NMR 
(400 MHz, CD3OCD3): δ = 3.72 (s, 3H, COOCH3), 4.92-
4.95 (m, 1H, CH), 5.41 (d, J = 3.2 Hz, 1H, CH), 6.88 
(d, J = 8.0 Hz, 1H, ArH), 7.22-7.36 (m, 5H, ArH), 7.50-
7.52 (m, 2H, ArH) ppm. 13C NMR (100.6 MHz, 
CD3OCD3): δ = 52.37 (CO2CH3), 59.86 (CH), 73.74 
(CH), 115.43 (CH), 115.56 (CH), 120.36 (CH), 126.88 
(2CH), 128.18 (CH), 128.84 (2CH), 142.49 (C), 145.56 
(C), 149.24 (C), 167.17 (C), 170.89 (C=O), 171.66 
(C=O) ppm. m/z (HRESI-MS) 332.11256, ([M + H]+, 
C17H18NO6, requires 332.11341). 
4.2.1.7. Synthesis of 2-(4-hydroxyphenyl)acetoyl-D,L-
Phe(-OH)-OMe, (5c) The general procedure described 
above was followed with 2-(4-hydroxyphenyl)acetic acid 
(0.380 g, 2.500 mmol) and HCl.H-D,L-Phe(-OH)-OMe 
to give compound 5c (0.735 g, 89.3%) as a light yellow 
oil. 1H NMR (400 MHz, CD3OCD3): δ = 3.42 (d, J = 8.8 
Hz, 2H, CH2), 3.70 (s, 3H, COOCH3), 4.72-4.75 (m, 1H, 
CH), 5.31 (d, J = 2.8 Hz, 1H, CH), 6.77 (d, J = 8.4 
Hz, 2H, ArH), 7.02 (d, J = 8.4 Hz, 2H, ArH), 7.26-7.38 
(m, 5H, ArH), 8.31 (br. s, 1H, NH) ppm. 13C NMR 
(100.6 MHz, CD3OCD3): δ = 42.42 (CH2), 52.32 
(CO2CH3), 59.27 (CH), 73.43 (CH), 115.93 (CH), 
126.89 (2CH), 127.25 (C), 128.08 (CH), 128.72 (2CH), 
131.13 (2CH), 142.27 (C), 156.96 (C), 171.42 (C=O), 
171.72 (C=O) ppm. m/z (HRESI-MS) 330.13331, ([M + 
H]+, C18H20NO5, requires 330.13415). 
4.2.1.8. Synthesis of 2-(3,4-dihydroxyphenyl)acetoyl-
D,L-Phe(-OH)-OMe, (5d) The general procedure 
described above was followed with 2-(3,4-
dihydroxyphenyl)acetic acid (0.420 g, 2.500 mmol) and 
HCl.H-D,L-Phe(-OH)-OMe to give compound 5d 
(0.739 g, 85.6%) as a light yellow oil. 1H NMR (400 
MHz, CD3OCD3): δ = 3.37 (d, J = 6.0 Hz, 2H, CH2), 
3.69 (s, 3H, COOCH3), 4.69-4.72 (m, 1H, CH), 5.28 (d, 
J = 2.8 Hz, 1H, CH), 6.55 (dd, J = 2.0 Hz, J = 8.0 Hz, 
1H, ArH), 6.75 (d, J = 2.0 Hz, 1H, ArH), 6.77 (d, J = 8.0 
Hz, 1H, ArH), 7.22-7.36 (m, 5H, ArH), 7.91 (br. s, 1H, 
NH) ppm. 13C NMR (100.6 MHz, CD3OCD3): δ = 42.74 
(CH2), 52.33 (CO2CH3), 59.29 (CH), 73.49 (CH), 
115.96 (CH), 117.31 (CH), 121.55 (CH), 126.90 (2CH), 
127.89 (C), 128.12 (CH), 128.72 (2CH), 142.20 (C), 
144.71 (C), 145.73 (C), 171.67 (C=O), 171.74 (C=O) 
ppm. m/z (HRESI-MS) 346.12851, ([M + H]+, 
C18H20NO6, requires 346.12906). 
4.2.1.9. Synthesis of p-coumaroyl-D,L-Phe(-OH)-OMe, 
(5e) The general procedure described above was 
followed with p-coumaric acid (0.410 g, 2.500 mmol) 
and HCl.H-D,L-Phe(-OH)-OMe to give compound 5e 
(0.680 g, 79.8%) as a as a yellow oil. 1H NMR (400 
MHz, CD3OCD3): δ = 3.71 (s, 3H, COOCH3), 4.93 (d, J 
= 3.2 Hz, 1H, CH), 5.35 (d, J = 3.2 Hz, 1H, CH), 6.74 
(d, J = 15.6 Hz, 1H, Ar-CH=CH-), 6.87 (d, J = 8.4 Hz, 
2H, ArH), 7.22-7.26 (m, 1H, ArH), 7.30-7.35 (m, 2H, 
ArH), 7.38 (d, J = 15.6 Hz, 1H, Ar-CH=CH-), 7.42 (d, J 
= 8.4 Hz, 2H, ArH), 7.44-7.47 (m, 2H, ArH) ppm. 13C 
NMR (100.6 MHz, CD3OCD3): δ = 52.37 (CO2CH3), 
59.56 (CH), 73.66 (CH), 116.46 (2CH), 118.70 (CH), 
126.92 (2CH), 127.49 (C), 128.13 (CH), 128.74 (2CH), 
130.24 (2CH), 141.14 (CH), 142.39 (C), 159.79 (C), 
166.91 (C=O), 171.60 (C=O) ppm. m/z (HRESI-MS) 
342.13374, ([M + H]+, C19H20NO5, requires 342.13415). 
4.2.1.10. Synthesis of caffeoyl-D,L-Phe(-OH)-OMe, (5f) 
The general procedure described above was followed 
with cafeic acid (0.450 g, 2.500 mmol) and HCl.H-D,L-
Phe(-OH)-OMe to give compound 5f (0.867 g, 97.1%) 
as a light yellow solid. (from ethyl acetate/petroleum 
ether). M.p. 182.0-183.0 °C. 1H NMR (400 MHz, 
CD3OCD3): δ = 3.71 (s, 3H, COOCH3), 4.90-4.93 (m, 
1H, CH), 5.37 (d, J = 3.2 Hz, 1H, CH), 6.69 (d, J = 
15.6 Hz, 1H, Ar-CH=CH-), 6.85 (d, J = 8.4 Hz, 1H, 
ArH), 6.96 (dd, J = 2.0 Hz, J = 8.4 Hz, 1H, ArH), 7.10 
(d, J = 2.0 Hz, 1H, ArH), 7.22-7.26 (m, 1H, ArH), 7.31-
7.36 (m, 3H, ArH + Ar-CH=CH-), 7.47-7.50 (m, 2H, 
ArH) ppm. 13C NMR (100.6 MHz, CD3OCD3): δ = 52.33 
(CO2CH3), 59.55 (CH), 73.76 (CH), 114.88 (CH), 
116.21 (CH), 118.99 (CH), 121.68 (CH), 126.96 (2CH), 
128.14 (CH), 128.31 (C), 128.75 (2CH), 141.34 (CH), 
142.49 (C), 146.11 (C), 147.82 (C), 166.68 (C=O), 
171.64 (C=O) ppm. m/z (HRESI-MS) 358.12837, ([M + 
H]+, C19H20NO6, requires 358.12906). 
4.2.1.11. Synthesis of hydrocaffeoyl-D,L-Phe(-OH)-
OMe, (5g) The general procedure described above was 
followed with hydrocaffeic acid (0.455 g, 2.500 mmol) 
and HCl.H-D,L-Phe(-OH)-OMe to give compound 5g 
(0.803 g, 89.4%) as a white solid. (from ethyl 
acetate). M.p. 174.0-175.0 °C. 1H NMR (400 MHz, 
CD3OD): δ = 2.41-2.44 (m, 2H, CH2), 2.59-2.61 (m, 2H, 
CH2), 3.72 (s, 3H, OCH3), 4.77 (d, J = 3.6 Hz, 1H, 
CH), 5.24 (d, J = 3.6 Hz, 1H, CH), 6.45 (dd, J = 2.0 
Hz, J = 8.0 Hz, 1H, ArH), 6.60 (d, J = 2.0 Hz, 1H, ArH), 
6.65 (d, J = 8.0 Hz, 1H, ArH), 7.24-7.39 (m, 5H, ArH) 
ppm. 13C NMR (100.6 MHz, CD3OCD3): δ = 32.14 
(CH2), 38.85 (CH2), 52.79 (OCH3), 59.99 (CH), 74.10 
(CH), 116.33 (CH), 116.41 (CH), 120.45 (CH), 127.19 
(2CH), 128.66 (CH), 129.16 (2CH), 133.73 (C), 142.28 
(C), 144.55 (C), 14.16 (C), 1702.31 (C=O), 175.64 
(C=O) ppm. m/z (HRESI-MS) 360.14382, ([M + H]+, 
C19H22NO6, requires 360.14471). 
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4.2.1.12. Synthesis of galloyl-D,L-Phe(-OH)-OMe, (5h) 
The general procedure described above was followed 
with gallic acid (0.425 g, 2.500 mmol) and HCl.H-D,L-
Phe(-OH)-OMe to give compound 5h (0.661 g, 76.2%) 
as a white solid. M.p. 104.0-105.0 °C. 1H NMR (400 
MHz, CD3OD): δ = 3.72 (s, 3H, COOCH3), 4.90-4.93 
(m, 1H, CH), 5.26 (br. d, J = 8.4 Hz, 1H, NH), 5.41 (d, 
J = 3.2 Hz, 1H, CH), 6.94 (s, 2H, ArH), 7.21-7.27 (m, 
1H, ArH), 7.31-7.36 (m, 2H, ArH), 7.49-7.51 (m, 2H, 
ArH), 8.07 (br. s, 3H, OH) ppm. 13C NMR (100.6 MHz, 
CD3OCD3): δ = 52.40 (CO2CH3), 59.91 (CH), 73.78 
(CH), 107.56 (2CH), 126.03 (C), 126.85 (2CH), 128.19 
(CH), 128.85 (2CH), 137.13 (C), 142.44 (C), 146.08 
(2C), 167.41 (C=O), 171.65 (C=O) ppm. m/z (HRESI-
MS) 348.10785, ([M + H]+, C17H18NO7, requires 
348.10833). 
4.2.1.13. Synthesis of 4-hydroxybenzoyl-L-Ala-OMe, 
(10a) The general procedure described above was 
followed with 4-hydroxybenzoic acid (0.345 g, 
2.500 mmol) and HCl.H-L-Ala-OMe to give compound 
10a (0.412 g, 73.9%) as a white solid (from ethyl 
acetate/petroleum ether). M.p. 168.0-169.0 °C. 1H NMR 
(400 MHz, CD3OCD3): δ = 1.48 (d, J = 7.2 Hz, 3H, 
CH3), 3.71 (s, 3H, COOCH3), 4.62-4.69 (m, 1H, CH), 
6.91 (d, J = 8.8 Hz, 2H, ArH), 7.76 (br. d, J = 6.4 Hz, 
1H, NH), 7.85 (d, J = 8.8 Hz, 2H, ArH), 8.97 (s, 1H, 
OH) ppm. 13C NMR (100.6 MHz, CD3OCD3): δ = 17.67 
(CH3), 49.22 (CH), 52.18 (CO2CH3), 115.70 (2CH), 
126.40 (C), 130.13 (2CH), 161.20 (C), 166.90 (C=O), 
174.13 (C=O) ppm. m/z (HRESI-MS) 224.09190, ([M + 
H]+, C11H14NO4, requires 224.09228). 
4.2.1.14. Synthesis of 3,4-dihydroxybenzoyl-L-Ala-OMe, 
(10b) The general procedure described above was 
followed with protocatechuic acid (0.385 g, 2.500 mmol) 
and HCl.H-L-Ala-OMe to give compound 10b (0.207 g, 
34.6%) as a light yellow oil. 1H NMR (400 MHz, 
CD3OCD3): δ = 1.48 (d, J = 7.2 Hz, 3H, CH3), 3.71 (s, 
3H, COOCH3), 4.62-4.66 (m, 1H, CH), 6.88 (d, J = 8.0 
Hz, 1H, ArH), 7.35-7.37 (m, 1H, ArH), 7.47 (d, J = 2.0 
Hz, 1H, ArH), 7.67 (br. s, 1H, NH) ppm. 13C NMR 
(100.6 MHz, CD3OCD3): δ = 17.63 (CH3), 49.22 
(CH), 52.18 (CO2CH3), 115.46 (CH), 115.67 (CH), 
120.47 (CH), 127.04 (C), 145.59 (C), 149.19 (C), 166.99 
(C=O), 174.15 (C=O) ppm. m/z (HRESI-MS) 
240.08646, ([M + H]+, C11H14NO5, requires 240.08720). 
4.2.1.15. Synthesis of 2-(4-hydroxyphenyl)acetoyl-L-Ala-
OMe, (10c) The general procedure described above was 
followed with 2-(4-hydroxyphenyl)acetic acid (0.380 g, 
2.500 mmol) and HCl.H-L-Ala-OMe to give compound 
10c (0.415 g, 69.9%) as a light pink solid (from ethyl 
acetate/petroleum ether). M.p. 97.0-98.0°C. 1H NMR 
(400 MHz, CDCl3): δ = 1.36 (d, J = 7.2 Hz, 3H, CH3), 
3.53 (s, 2H, ARCH2), 3.73 (s, 3H, COOCH3), 4.57-4.61 
(m, 1H, CH), 6.01 (br. s, 1H, NH), 6.81 (d, J = 7.6 Hz, 
2H, ArH), 7.13 (d, J = 7.6 Hz, 2H, ArH) ppm. 13C NMR 
(100.6 MHz, CDCl3): δ = 17.84 (CH3), 42.46 (CH2), 
48.75 (CH), 52.18 (CO2CH3), 115.92 (2CH), 127.52 
(C), 130.99 (2CH), 157.02 (C), 171.33 (C=O), 173.88 
(C=O) ppm. m/z (HRESI-MS) 238.10728, ([M + H]+, 
C12H16NO4, requires 238.10793). 
4.2.1.16. Synthesis of 2-(3,4-dihydroxyphenyl)acetoyl-L-
Ala-OMe, (10d) The general procedure described above 
was followed with 2-(3,4-dihydroxyphenyl)acetic acid 
(0.420 g, 2.500 mmol) and HCl.H-L-Ala-OMe to give 
compound 10d (0.327 g, 51.7%) as a light pink oil. 1H 
NMR (400 MHz, CD3OCD3): δ = 1.34 (d, J = 7.2 Hz, 
3H, CH3), 3.40 (s, 2H, ARCH2), 3.67 (s, 3H, 
COOCH3), 4.43-4.46 (m, 1H, CH), 6.65 (dd, J = 7.6 
Hz, J = 2.0 Hz 1H, ArH), 6.76 (d, J = 7.6 Hz, 1H, ArH), 
6.84 (d, J = 2.0 Hz, 1H, ArH), 7.37 (br. s, 1H, NH), 7.90 
(br. s, 2H, 2OH) ppm. 13C NMR (100.6 MHz, 
CD3OCD3): δ = 17.82 (CH3), 42.75 (CH2), 48.78 
(CH), 52.20 (CO2CH3), 115.89 (CH), 117.10 (CH), 
121.36 (CH), 128.19 (C), 144.72 (C), 145.76 (C), 171.45 
(C=O), 173.87 (C=O) ppm. m/z (HRESI-MS) 
254.10208, ([M + H]+, C12H16NO5, requires 254.10285). 
4.2.1.17. Synthesis of p-coumaroyl-L-Ala-OMe, (10e) 
The general procedure described above was followed 
with p-coumaric acid (0.410 g, 2.500 mmol) and HCl.H-
L-Ala-OMe to give compound 10e (0.485 g, 77.8%) as a 
white solid (from methanol/diethyl ether). M.p. 123.0-
125.0°C. 1H NMR (400 MHz, CD3OCD3): δ = 1.42 (d, J 
= 7.2 Hz, 3H, CH3), 3.71 (s, 3H, COOCH3), 4.56-4.64 
(m, 1H, CH), 6.59 (d, J = 15.6 Hz, 1H, Ar-CH=CH-), 
6.89 (d, J = 8.8 Hz, 2H, ArH), 7.46-7.53 (m, 4H, ArH + 
NH + Ar-CH=CH-), 8.89 (br. s, 1H, OH) ppm. 13C NMR 
(100.6 MHz, CD3OCD3): δ = 17.99 (CH3), 48.80 
(CH), 52.22 (CO2CH3), 116.56 (2CH), 118.88 (CH), 
127.60 (C), 130.21 (2CH), 140.91 (CH), 159.85 (C), 
166.18 (C=O), 174.01 (C=O) ppm. m/z (HRESI-MS) 
250.10705, ([M + H]+, C13H16NO4, requires 250.10793). 
4.2.1.18. Synthesis of caffeoyl-L-Ala-OMe, (10f) The 
general procedure described above was followed with 
caffeic acid (0.450 g, 2.500 mmol) and HCl.H-L-Ala-
OMe to give compound 10f (0.486 g, 73.3%) as a white 
solid. (from ethyl acetate/petroleum ether). M.p. 151.0-
152.0 °C. 1H NMR (400 MHz, CD3COCD3): δ = 1.42 (d, 
J = 7.2 Hz, 3H, CH3), 3.71 (s, 3H, COOCH3), 4.56-4.63 
(m, 1H, CH), 6.54 (d, J = 15.6 Hz, 1H, Ar-CH=CH-), 
6.87 (d, J = 8.0 Hz, 1H, ArH), 6.96-6.99 (m, 1H, ArH), 
7.11 (d, J = 2.0 Hz, 1H, ArH), 7.45 (d, J = 15.6 Hz, 1H, 
Ar-CH=CH-), 7.52 (br. d, J = 7.2 Hz, 1H, NH), 8.15 (s, 
1H, OH), 8.38 (s, 1H, OH) ppm. 13C NMR (100.6 MHz, 
CD3OCD3): δ = 17.95 (CH3), 48.80 (CH), 52.22 
(CO2CH3), 114.84 (CH), 116.29 (CH), 118.95 (CH), 
121.67 (CH), 128.30 (C), 141.27 (CH), 146.22 (C), 
147.92 (C), 166.19 (C=O), 174.01 (C=O) ppm. m/z 
(HRESI-MS) 266.10191, ([M + H]+, C13H16NO5, 
requires 266.10285). 
4.2.1.19. Synthesis of hydrocaffeoyl-L-Ala-OMe, (10g) 
The general procedure described above was followed 
with hydrocaffeic acid (0.455 g, 2.500 mmol) and 
HCl.H-L-Ala-OMe to give compound 10g (0.414 g, 
62.0%) as a colourless oil. 1H NMR (400 MHz, 
CD3OCD3): δ = 1.33 (d, J = 7.2 Hz, 3H, CH3), 2.45-
2.49 (m, 2H, CH2), 2.77-2.81 (m, 2H, CH2), 3.68 (s, 3H, 
OCH3), 4.44-4.51 (m, 1H, CH), 6.57 (dd, J = 2.0 Hz, J 
= 8.0 Hz, 1H, ArH), 6.73-6.75 (m, 2H, ArH), 7.44 (br. d, 
J = 6.8 Hz, 1H, NH), 7.75 (br. s, 2H, 2OH) ppm. 13C 
NMR (100.6 MHz, CD3OCD3): δ = 17.78 (CH3), 31.60 
(CH2), 38.52 (CH2), 48.66 (CH), 52.21 (CO2CH3), 
115.93 (CH), 116.22 (CH), 120.30 (CH), 133.84 (C), 
144.02 (C), 145.68 (C), 172.71 (C=O), 173.88 (C=O) 
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ppm. m/z (HRESI-MS) 268.11757, ([M + H]+, 
C13H18NO5, requires 268.11850). 
4.2.2. Synthesis of the methyl ester of N-(4-
hydroxybenzoyl) dehydroalanine 
Synthesis of 4-hydroxybenzoyl-Ala-OMe (4a) To a 
solution of 1a (0.239 g, 1.000 mmol) in 
dry acetonitrile (0.200 mmol dm-3), 0.1 equiv. 
of dimethylaminopyridine was added, followed by 2.5 
equiv. of tert-butyldicarbonate. The reaction was 
monitored by TLC (ethyl acetate) until all the reactant 
had been fully tert-butyloxycarbonylated. The solvent 
was evaporated at reduced pressure and the residue was 
dissolved in ethyl acetate (60 cm3) and washed with 
KHSO4 (1 mol dm-3), NaHCO3 (1 mol dm-3) and brine (3 
times 15 cm3 each). The organic layer was dried with 
MgSO4 and the solvent evaporated at reduced 
pressure. Removal of the solvent afforded 2a (0.300 g, 
68.4%). 1H NMR (400 MHz, CDCl3): δ = 1.47 (s, 9H, 
CH3 Boc), 1.57 (s, 9H, CH3 Boc), 3.82 (s, 3H, 
COOCH3), 4.46 (dd, J = 3.6 Hz, J = 11.2 Hz, 1H, CH2), 
4.61 (dd, J = 3.6 Hz, J = 11.2 Hz, 1H, CH2), 5.01-5.04 
(m, 1H, CH), 7.00 (d, J = 7.6 Hz, 1H, NH), 7.28 (d, J = 
8.8 Hz, 2H, ArH), 7.86 (d, J = 8.8 Hz, 2H, ArH) 
ppm. 13C NMR (100.6 MHz, CDCl3): δ = 27.64 
[2C(CH3)3], 52.48 (CH), 52.95 (CO2CH3),  66.05 
(CH2), 83.08 [OC(CH3)3], 84.07 [OC(CH3)3], 121.36 
(2CH), 128.66 (2CH), 130.86 (C), 151.11 (C=O), 153.23 
(C=O), 153.82 (C), 166.18 (C=O), 169.75 (C=O) ppm. 
m/z (HRESI-MS) 440.19085, ([M + H]+, C21H30NO9, 
requires 440.19206). Compound 2a (0.300 g, 0.684 
mmol) was redissolved in acetonitrile (0.200 mol dm-3) 
and 4% in volume of N,N,N’,N’-tetramethylguanidine 
was added, stirring was continued and the reaction 
followed by TLC. When the bis-tert-butyloxycarbonate 
derivative was consumed, the solvent was evaporated at 
reduced pressure. The residue was dissolved in ethyl 
acetate (60 cm3) and washed with KHSO4 (1 mol dm-3), 
and brine (3 times 15 cm3 each). The organic layer was 
dried with MgSO4 and the solvent evaporated at reduced 
pressure. Removal of the solvent afforded 3a (0.068 g, 
31.0%) 1H NMR (400 MHz, CDCl3): δ = 1.58 (s, 9H, 
CH3 Boc), 3.91 (s, 3H, COOCH3), 6.01 (s, 1H, CH2), 
6.79 (s, 1H, CH2), 7.30 (d, J = 8.8 Hz, 2H, ArH), 7.87 
(d, J = 8.8 Hz, 2H, ArH), 8.49 (br. s, 1H, NH) ppm. 13C 
NMR (100.6 MHz, CDCl3): δ = 27.66 [C(CH3)3], 53.13 
(CO2CH3), 84.19 [OC(CH3)3], 109.03 (CH2), 121.61 
(2CH), 128.44 (2CH), 130.96 (C), 131.66 (C), 151.14 
(C=O), 153.90 (C), 164.75 (C=O), 164.87 (C=O) ppm. 
m/z (HRESI-MS) 322.12785, ([M + H]+, C16H20NO6, 
requires 322.12906). Compound 3a (0.068 g, 0.212 
mmol) was dissolved in dichloromethane (0.1 mol dm-3) 
and 25% of TFA was slowly added with vigorous 
stirring. The reaction was monitored by TLC and when 
no starting material was detected (≈1 hour) an additional 
50 mL of dichloromethane were added. The organic 
phase was washed with NaHCO3 (1 mol dm-3) and brine 
(3 times 15 cm3 each). The organic layer was dried with 
MgSO4 and the solvent evaporated at reduced pressure to 
give compound 4a (0.022 g, 47.1%) as a white solid. 
M.p. 205.0-206.0 °C. 1H NMR (400 MHz, CD3OCD3): δ 
= 3.89 (s, 3H, COOCH3), 5.84 (d, J = 1.2 Hz, 1H, CH2), 
6.57 (d, J = 1.6, 1H, CH2), 6.99 (d, J = 8.8 Hz, 2H, 
ArH), 7.84 (d, J = 8.8 Hz, 2H, ArH), 8.71 (br. s, 1H, NH) 
ppm. 13C NMR (100.6 MHz, CD3OCD3): δ = 53.20 
(CO2CH3), 107.96, 108.06 (CH2), 116.15 (2CH), 
126.28 (C), 129.98 (2CH), 133.29 (C), 161.76 (C), 
165.23, 165.27 (C=O), 165.56, 165.63 (C=O) ppm. m/z 
(HRESI-MS) 222.07623, ([M + H]+, C11H12NO4, 
requires 222.07663). 
4.2.3. Synthesis of the methyl esters of N-phenoyl and N-
catechoyl dehydroalanine  
General one-pot procedure for the synthesis of the 
methyl esters of N-phenoyl and N-catechoyl 
dehydroalanine  
To a solution of the methyl ester of N-acyl serine in 
dry acetonitrile (0.200 mol.dm-3), 0.1 equiv. 
of dimethylaminopyridine was added, followed by 2.5 
equiv. of tert-butyldicarbonate for monohydroxylated 
phenol derivatives or 3.5 equiv. for catechol derivatives, 
under rapid stirring at room temperature. The reaction 
was monitored by TLC (ethyl acetate) until all the 
reactant had been fully tert-butyloxycarbonylated. Then, 
4% in volume of N,N,N’,N’-tetramethylguanidine was 
added, stirring was continued and the reaction followed 
by TLC. When all the tert-butyloxycarbonylated 
derivative had beeen consumed, the solvent was 
evaporated at reduced pressure. The residue was 
redissolved in dichloromethane (0.1 mol dm-3) and 25% 
of TFA was slowly added with vigorous stirring. The 
reaction was monitored by TLC and when no starting 
material was detected (≈1 hour) an additional 50 mL of 
dichloromethane were added. The organic phase was 
washed with KHSO4 (1 mol dm-3), NaHCO3 (1 mol dm-3) 
and brine (3 times 15 cm3 each). The organic layer was 
dried with MgSO4 and the solvent evaporated at reduced 
pressure.  
4.2.3.1. Synthesis of 4-hydroxybenzoyl-Ala-OMe, (4a) 
The general procedure described above was followed 
with 1a (0.239 g, 1.000 mmol) to give compound 4a 
(0.104 g, 47.1%).  
4.2.3.2. Synthesis of 2-(4-hydroxyphenyl)acetoyl-Ala-
OMe, (4c) The general procedure described above was 
followed with 1c (0.253 g, 1.000 mmol) to give 
compound 4c (0.085 g, 36.2%) as a light yellow oil that 
solidified on standing. M.p. 102.0-103.0 °C. 1H NMR 
(400 MHz, CD3OCD3): δ = 3.66 (s, 2H, CH2), 3.80 (s, 
3H, COOCH3), 5.74 (d, J = 1.2 Hz, 1H, CH2), 6.52 (s, 
1H, CH2), 6.85 (d, J = 8.8 Hz, 2H, ArH), 7.22 (d, J = 
8.8 Hz, 2H, ArH), 8.33 (br. s, 1H, NH) ppm. 13C NMR 
(100.6 MHz, CD3OCD3): δ = 43.76 (CH2), 53.06 
(CO2CH3), 107.65 (CH2), 116.22 (CH), 116.27 (CH), 
126.79 (C), 131.26 (2CH), 132.91 (C), 157.38 (C), 
164.80 (C=O), 170.95 (C=O) ppm. m/z (HRESI-MS) 
236.09161, ([M + H]+, C12H14NO4, requires 236.09228). 
4.2.3.3. Synthesis of p-coumaroyl-Ala-OMe, (4e) The 
general procedure described above was followed with 1e 
(0.265 g, 1.000 mmol) to give compound 4e (0.169 g, 
68.4%) as a white solid. M.p. 145.0-146.0 °C. 1H NMR 
(400 MHz, CD3OCD3): δ = 3.86 (s, 3H, COOCH3), 5.82 
(s, 1H, CH2), 6.68 (s, 1H, CH2), 6.89-6.93 (m, 3H, 
ArH + Ar-CH=CH-), 7.54 (d, J = 8.4 Hz, 2H, ArH), 7.59 
(d, J = 15.6 Hz, 1H, Ar-CH=CH-) ppm. 13C NMR (100.6 
MHz, CD3OCD3): δ = 53.06 (CO2CH3), 107.95 (CH2), 
116.58 (2CH), 119.10 (CH), 127.50 (C), 130.58 (2CH), 
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133.40 (C), 142.33 (CH), 160.11 (C), 164.89 (C=O), 
165.51 (C=O) ppm. m/z (HRESI-MS) 248.09138, ([M + 
H]+, C13H14NO4, requires 248.09228). 
4.2.3.4. Synthesis of caffeoyl-Ala-OMe, (4f) The 
general procedure described above was followed with 1f 
(0.281 g, 1.000 mmol) to give compound 4f (0.068 g, 
25.8%) as a light yellow solid. M.p. 174.0-175.0 °C. 1H 
NMR (400 MHz, CD3OCD3): δ = 3.86 (s, 3H, 
COOCH3), 5.81 (s, 1H, CH2), 6.67 (s, 1H, CH2), 6.85 
(d, J = 15.6 Hz, 1H, Ar-CH=CH-), 6.89 (d, J = 8.4 Hz, 
1H, ArH), 7.04 (dd, J = 2.0 Hz, J = 8.4 Hz, 1H, ArH), 
7.17 (d, J = 2.0 Hz, 1H, ArH), 7.48 (d, J = 15.6 Hz, 1H, 
Ar-CH=CH-) ppm. 13C NMR (100.6 MHz, 
CD3OCD3): δ = 53.05 (CO2CH3), 107.98 (CH2), 115.06 
(CH), 116.24 (CH), 119.13 (CH), 122.08 (CH), 128.13 
(C), 133.32 (C), 142.72 (CH), 146.15 (C), 148.15 (C), 
164.89 (C=O), 165.55 (C=O) ppm. m/z (HRESI-MS) 
264.08645, ([M + H]+, C13H14NO5, requires 264.08720). 
4.2.4. Synthesis of the methyl ester of N-caffeoyl 
dehydrophenylalanine 
Synthesis of caffeoyl-Z-Phe-OMe, (8f) To a solution of 
5f (0.357 g, 1.000 mmol) in dry acetonitrile (0.200 mol 
dm-3), 0.1 equiv. of dimethylaminopyridine was added, 
followed by 3.5 equiv. of tert-butyldicarbonate. The 
reaction was monitored by TLC (ethyl acetate) until all 
the reactant had been fully tert-butyloxycarbonylated. 
The solvent was evaporated at reduced pressure and the 
residue was dissolved in ethyl acetate (100 cm3) and 
washed with KHSO4 (1 mol dm-3), NaHCO3 (1 mol dm-3) 
and brine (3 times 25 cm3 each). The organic layer was 
dried with MgSO4 and the solvent evaporated at reduced 
pressure. Removal of the solvent afforded 6f (0.402 g, 
61.1%). 1H NMR (400 MHz, CDCl3): δ = 1.47 (s, 9H, 
CH3 Boc), 1.56 (s, 9H, CH3 Boc), 1.57 (s, 9H, CH3 Boc), 
3.77 (s, 3H, COOCH3), 5.19 (dd, J = 3.2 Hz, J = 9.4 Hz, 
1H, CH), 6.18 (d, J = 3.2 Hz, 1H, CH), 6.35 (d, J = 
15.6 Hz, 1H, Ar-CH=CH-), 7.28-7.40 (m, 8H, ArH), 
7.46 (d, J = 15.6 Hz, 1H, Ar-CH=CH-) ppm. 13C NMR 
(100.6 MHz, CDCl3): δ = 27.59 [C(CH3)3], 27.60 
[C(CH3)3], 27.63 [C(CH3)3], 52.79 (CO2CH3),  56.56 
(CH), 77.15 (CH), 83.32 [OC(CH3)3], 84.07 
[OC(CH3)3], 84.09 [OC(CH3)3], 120.56 (CH), 121.97 
(CH), 123.41 (CH), 125.95 (2CH), 126.13 (CH), 128.57 
(2CH), 128.60 (CH), 133.21 (C), 135.90 (C), 140.39 
(CH), 142.76 (C), 143.53 (C), 150.39 (C=O), 150.52 
(C=O), 152.26 (C=O), 165.08 (C=O), 169.80 
(C=O) ppm. m/z (HRESI-MS) 658.28506, ([M + H]+, 
C34H44NO12, requires 658.28635). Compound 6f (0.402 
g, 0.611 mmol)  was redissolved in acetonitrile (0.200  
mol dm-3) and 4% in volume of N,N,N’,N’-
tetramethylguanidine added, stirring was continued and 
the reaction followed by TLC. When all the tris-tert-
butyloxycarbonate derivative was consumed, the solvent 
was evaporated at reduced pressure. The residue was 
dissolved in ethyl acetate (100 cm3) and washed with 
KHSO4 (1 mol dm-3), and brine (3 times 25 cm3 each). 
The organic layer was dried with MgSO4 and the solvent 
evaporated at reduced pressure. Removal of the solvent 
afforded 7f (0.255 g, 77.3%) as a light yellow solid. M.p. 
149.0-150.0  1H NMR (400 MHz, CDCl3): δ = 1.56 (s, 
9H, CH3 Boc), 1.57 (s, 9H, CH3 Boc), 3.87 (s, 3H, 
COOCH3), 6.47 (d, J = 15.6 Hz, 1H, Ar-CH=CH-), 7.29-
7.49 (m, 8H, ArH + CH), 7.62 (d, J = 15.6 Hz, 1H, Ar-
CH=CH-) ppm. 13C NMR (100.6 MHz, CDCl3): δ = 
27.60 [2C(CH3)3], 52.78 (CO2CH3), 84.12 [OC(CH3)3], 
84.15 [OC(CH3)3], 120.49 (CH), 122.01 (CH), 123.47 
(CH), 123.93 (C), 126.45 (CH), 128.63 (CH), 128.91 
(CH), 129.37 (CH), 129.54 (CH), 129.75 (CH), 131.98 
(CH), 133.15 (C), 133.77 (C), 141.43 (CH), 142.79 (C), 
143.71 (C), 150.39 (C=O), 150.56 (C=O), 163.73 (C=O), 
165.71 (C=O) ppm. m/z (HRESI-MS) 540.22264, ([M + 
H]+, C29H34NO9, requires 540.22336). Compound 7f 
(0.255 g, 0.473 mmol) was dissolved in dichloromethane 
(0.1 mol dm-3) and 25% of TFA was slowly added with 
vigorous stirring. The reaction was monitored by TLC 
and when no starting material was detected (≈1 hour) an 
additional 50 mL of dichloromethane were added. The 
organic phase was washed with  NaHCO3 (1 mol dm-3) 
and brine (3 times 15 cm3 each). The organic layer was 
dried with MgSO4 and the solvent evaporated at reduced 
pressure to give compound 8f (0.097 g, 60.7%) as an 
orange oil. 1H NMR (400 MHz, CD3OCD3): δ = 3.80 (s, 
3H, COOCH3), 6.74 (d, J = 15.6 Hz, 1H, Ar-CH=CH-), 
6.89 (d, J = 8.0 Hz, 1H, ArH), 7.03 (dd, J = 2.0 Hz, J = 
8.0 Hz, 1H, ArH), 7.16 (d, J = 2.0 Hz, 1H, ArH), 7.27 (s, 
1H, CH), 7.34-7.44 (m, 3H, ArH), 7.52 (d, J = 15.6 Hz, 
1H, Ar-CH=CH-), 7.66 (d, J = 7.2 Hz, 2H, ArH), 8.84 
(br. s, 1H, NH) ppm. 13C NMR (100.6 MHz, 
CD3OCD3): δ = 52.47 (CO2CH3), 114.94 (CH), 116.30 
(CH), 118.25 (CH), 122.00 (CH), 127.53 (C), 128.10 
(C), 129.38 (2CH), 129.91 (CH), 130.64 (2CH), 131.34 
(CH), 134,99 (C), 142.60 (CH), 146.19 (C), 148.17 (C), 
166.65 (C=O), 166.49 (C=O) ppm. m/z (HRESI-MS) 
340.11824, ([M + H]+, C19H18NO5, requires 340.11850). 
4.2.5. Synthesis of the methyl esters of N-phenoyl and N-
catechoyl dehydrophenylalanine 
General one-pot procedure for the synthesis of the 
methyl esters of N-phenoyl and N-catechoyl 
dehydrophenylalanine 
To a solution of the methyl ester of N-acyl phenylserine 
in dry acetonitrile (0.200 mol dm-3), 0.1 equiv. 
of dimethylaminopyridine was added, followed by 2.5 
equiv. of tert-butyldicarbonate for monohydroxylated 
fenol derivatives or 3.5 equiv. for catechol derivatives, 
under rapid stirring at room temperature. The reaction 
was monitored by TLC (ethyl acetate) until all the 
reactant had been fully tert-butyloxycarbonylated. Then, 
4% in volume of N,N,N’,N’-tetramethylguanidine was 
added, stirring was continued and the reaction followed 
by TLC. When all the tert-butyloxycarbonylated 
derivative had been consumed, the solvent was 
evaporated at reduced pressure. The residue was 
redissolved in dichloromethane (0.1 mol dm-3) and 25% 
of TFA was slowly added with vigorous stirring. The 
reaction was monitored by TLC and when no starting 
material was detected (≈1 hour) an additional 50 mL of 
dichloromethane were added. The organic phase was 
washed with KHSO4 (1 mol dm-3), NaHCO3 (1 mol dm-3) 
and brine (3 times 15 cm3 each). The organic layer was 
dried with MgSO4 and the solvent evaporated at reduced 
pressure.  
4.2.5.1. Synthesis of 4-hydroxybenzoyl-Z-Phe-OMe, 
(8a) The general procedure described above was 
followed with 5a (0.315 g, 1.000 mmol) to give 
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compound 8a (0.168 g, 56.5%) as light green solid. M.p. 
118.0-119.0 °C. 1H NMR (400 MHz, CD3OCD3): δ = 
3.79 (s, 3H, COOCH3), 6.97 (d, J = 8.4 Hz, 2H, ArH), 
7.35-7.41 (m, 4H, ArH + CH), 7.67-7.96 (m, 2H, ArH), 
7.96 (d, J = 8.4 Hz, 2H, ArH), 9.04 (br. s, 1H, NH) 
ppm. 13C NMR (100.6 MHz, CD3OCD3): δ = 52.46 
(CO2CH3), 115.97 (2CH), 125.69 (C), 127.77 (C), 
129.36 (2CH), 129.97 (CH), 130.58 (2CH), 130.62 
(2CH), 132.90 (CH), 134.80 (C), 135.00 (C), 161.96 
(C=O), 166.54 (C=O) ppm. m/z (HRESI-MS) 
298.10797, ([M + H]+, C17H16NO4, requires 298.10793). 
4.2.5.2. Synthesis of protocatechoyl-Z-Phe-OMe, (8b) 
The general procedure described above was followed 
with 5b (0.331 g, 1.000 mmol) to give compound 8b 
(0.064 g, 20.5%) as a light orange oil. 1H NMR (400 
MHz, CD3OCD3): δ = 3.79 (s, 3H, COOCH3), 6.94 (d, J 
= 8.4 Hz, 1H, ArH), 7.36-7.42 (m, 4H, ArH + CH), 
7.50 (dd, J = 2.0 Hz, J = 8.4 Hz, 1H, ArH), 7.57 (d, J = 
1.0 Hz, 2H, ArH), 7.66-7.68 (m, 2H, ArH) ppm. 13C 
NMR (100.6 MHz, CD3OCD3): δ = 52.45 (CO2CH3), 
115.63 (CH), 115.96 (CH), 121.01 (CH), 126.63 (C), 
127.81 (C), 129.37 (2CH), 129.95 (CH), 130.64 (2CH), 
132.75 (CH), 135.09 (C), 145.69 (C), 149.60 (C), 166.56 
(2C=O) ppm. m/z (HRESI-MS) 314.10183, ([M + H]+, 
C17H16NO5, requires 314.10285). 
4.2.5.3. Synthesis of 2-(4-hydroxyphenyl)acetoyl-Z-
Phe-OMe, (8c) The general procedure described above 
was followed with 5c (0.329 g, 1.000 mmol) to give 
compound 8c (0.196 g, 62.9%) as yellow solid. M.p. 
54.0-55.0 °C. 1H NMR (400 MHz, CD3OCD3): δ = 3.63 
(s, 2H, CH2), 3.76 (s, 3H, COOCH3), 6.86 (d, J = 8.4 Hz, 
2H, ArH), 7.25-7.33 (m, 6H, ArH + CH), 7.46-7.50 (m, 
2H, ArH), 8.64 (br. s, 1H, NH) ppm. 13C NMR (100.6 
MHz, CD3OCD3): δ = 42.88 (CH2), 52.41 (CO2CH3), 
116.07 (2CH), 126.77 (C), 127.23 (C), 129.23 (2CH), 
129.91 (CH), 130.68 (2CH), 131.20 (2CH), 132.39 (CH), 
134.61 (C), 157.23 (C), 166.28 (C=O), 171.00 (C=O) 
ppm. m/z (HRESI-MS) 312.12415, ([M + H]+, 
C18H18NO4, requires 312.12358). 
4.2.5.4. Synthesis of 2-(3,4-dihydroxyphenyl)acetoyl-Z-
Phe-OMe, (8d) The general procedure described above 
was followed with 5d (0.345 g, 1.000 mmol) to give 
compound 8d (0.142 g, 43.3%) as a light yellow oil. 1H 
NMR (400 MHz, CD3OCD3): δ = 3.57 (s, 2H, CH2), 3.76 
(s, 3H, COOCH3), 6.76 (dd, J = 1.6 Hz, J = 8.0 Hz, 1H, 
ArH), 6.84 (d, J = 8.0 Hz, 1H, ArH), 6.94 (d, J = 1.6 Hz, 
1H, ArH), 7.22 (s, 1H, CH), 7.30-7.32 (m, 3H, ArH), 
7.47-7.49 (m, 2H, ArH), 7.91 (br. s, 1H, 2OH), 8.48 (s, 
1H, NH) ppm. 13C NMR (100.6 MHz, CD3OCD3): δ = 
43.22 (CH2), 52.40 (CO2CH3), 116.02 (CH), 117.25 
(CH), 121.64 (CH), 127.26 (C), 127.62 (C), 129.29 
(2CH), 129.90 (CH), 130.75 (2CH), 132.05 (CH), 134.70 
(C), 144.88 (C), 145.89 (C), 166.34 (C=O), 170.61 
(C=O) ppm. m/z (HRESI-MS) 328.11887, ([M + H]+, 
C18H18NO5, requires 328.11850). 
4.2.5.5. Synthesis of p-coumaroyl-Z-Phe-OMe, (8e) The 
general procedure described above was followed with 5e 
(0.341 g, 1.000 mmol) to give compound 8e (0.194 g, 
60.1%) as a light yellow solid. (from ethyl 
acetate/petroleum ether). M.p. 187.0-188.0 °C. 1H NMR 
(400 MHz, CD3OCD3): δ = 3.80 (s, 3H, COOCH3), 6.80 
(d, J = 15.6 Hz, 1H, Ar-CH=CH-), 6.92 (d, J = 8.4 Hz, 
2H, ArH), 7.28 (s, 1H, CH), 7.35-7.44 (m, 3H, ArH), 
7.52 (d, J = 8.4 Hz, 2H, ArH), 7.59 (d, J = 15.6 Hz, 1H, 
Ar-CH=CH-), 7.67 (d, J = 7.2 Hz, 2H, ArH), 8.88 (br. s, 
1H, NH) ppm. 13C NMR (100.6 MHz, CD3OCD3): δ = 
51.47 (CO2CH3), 115.63 (2CH), 117.17 (CH), 126.37 
(C), 126.67 (C), 128.38 (2CH), 128.91 (CH), 129.49 
(2CH), 129.65 (2CH), 130.41 (CH), 133,99 (C), 141.27 
(CH), 159.20 (C), 164.69 (C=O), 165.49 (C=O) ppm. 
m/z (HRESI-MS) 324.12348, ([M + H]+, C19H18NO4, 
requires 324.12358). 
4.2.5.6. Synthesis of caffeoyl-Z-Phe-OMe, (8f) The 
general procedure described above was followed with 5f 
(0.357 g, 1.000 mmol) to give compound 8f (0.177 g, 
54.5%).  
4.2.5.7. Synthesis of hydrocaffeoyl-Z-Phe-OMe, (8g) 
The general procedure described above was followed 
with 5g (0.359 g, 1.000 mmol) to give compound 8g 
(0.177 g, 52.0%) as a light yellow oil. 1H NMR (400 
MHz, CD3OCD3): δ = 2.67 (t, J = 7.2 Hz, 2H, CH2), 2.87 
(t, J = 7.2 Hz, 2H, CH2), 3.77 (s, 3H, OCH3), 6.63 (dd, J 
= 2.0 Hz, J = 8.0 Hz, 1H, ArH), 6.78 (d, J = 8.0 Hz, 1H, 
ArH), 6.79 (d, J = 2.0 Hz, 1H, ArH), 7.19 (s, 1H, CH), 
7.33-7.39 (m, 3H, ArH), 7.49-7.51 (m, 2H, ArH), 7.77 
(br. s, 2H, 2OH), 8.68 (s, 1H, NH) ppm. 13C NMR (100.6 
MHz, CD3OCD3): δ = 31.28 (CH2), 38.54 (CH2), 52.40 
(CO2CH3), 115.99 (CH), 116.38 (CH), 120.48 (CH), 
127.67 (C), 129.37 (2CH), 129.82 (CH), 130.62 (2CH), 
131.53 (CH), 133.80 (C), 134.73 (C), 144.14 (C), 145.76 
(C), 166.42 (C=O), 172.32 (C=O) ppm. m/z (HRESI-
MS) 342.13368, ([M + H]+, C19H20NO5, requires 
342.13415). 
4.2.5.8. Attempted synthesis of galloyl-Z-Phe-OMe, 
(8h) The general procedure described above was 
followed with 5h (0.347 g, 1.000 mmol) and 4.5 equiv. 
of tert-butyldicarbonate to give compound H-Z-Phe-
OMe (0.087 g, 48.8%) as a light yellow oil. 1H NMR 
(400 MHz, CD3OCD3): δ = 3.77 (s, 3H, COOCH3), 7.13 
(s, 1H, CH), 7.28-7.42 (m, 3H, ArH), 7.65-7.67 (m, 2H, 
ArH) ppm. 13C NMR (100.6 MHz, CD3OCD3): δ = 52.31 
(CO2CH3), 129.24 (2CH), 129.46 (CH), 129.95 (CH), 
130.53 (2CH), 135.49 (C), 156.97 (C), 167.23 (C=O) 
ppm. m/z (HRESI-MS) 178.10899, ([M + H]+, 
C10H12NO2, requires 178.08680). 
4.2.6. Synthesis of C-deprotected N-phenoyl and N-
catechoyl dehydrophenylalanines  
4.2.6.1. Synthesis of protocatechoyl-Z-Phe-OH, (9b) To 
a solution of 5b (0.331 g, 1.000 mmol) in dry acetonitrile 
(0.200 mol dm-3), 0.1 equiv. of DMAP was added, 
followed by 3.5 equiv. of tert-butyldicarbonate. The 
reaction was monitored by TLC (ethyl acetate) until all 
the reactant had been fully tert-butyloxycarbonylated. 
Then 4% in volume of TMG was added, stirring was 
continued and the reaction followed by TLC. When all 
the tert-butyloxycarbonylated derivative was consumed, 
the solvent was evaporated at reduced pressure. The 
residue was dissolved in ethyl acetate (100 cm3) and 
washed with KHSO4 (1 mol dm-3), and brine (3 times 25 
cm3 each). The organic layer was dried with MgSO4 and 
the solvent evaporated at reduced pressure. Removal of 
the solvent afforded  7b (0.372 g, 72.5%) as a yellow 
  
12 
solid. 1H NMR (400 MHz, CDCl3): δ = 1.49 (s, 9H, CH3 
Boc), 1.56 (s, 9H, CH3 Boc), 3.87 (s, 3H, OCH3), 6.88 
(d, J = 8.4 Hz, 1H, ArH), 7.33-7.38 (m, 3H, ArH + 
CH), 7.44-7.51 (m, 5H, ArH), 7.49 (s, 1H, OH), 7.96 (s, 
1H, OH) ppm. 13C NMR (100.6 MHz, CDCl3): δ = 27.55 
[C(CH3)3], 27.60 [C(CH3)3], 52.93 (CO2CH3), 85.00 
[2C(CH3)3], 117.82 (CH), 117.85 (C), 122.71 (CH), 
127.58 (CH), 128.70 (CH), 128.84 (CH), 129.69 (CH), 
130.85 (CH), 130.97 (CH), 132.31 (CH), 133.30 (C), 
133.57 (C), 138.94 (C), 150.96 (C=O), 152.48 (C=O), 
162.65 (C=O), 167.74 (C=O) ppm. m/z (HRESI-MS) 
514.18352, ([M + H]+, C27H32NO9, requires 514.20771). 
Compound 7b (0.257 g, 0.500 mmol) was then dissolved 
in dioxane (0.2 mol dm-3), followed by addition of 3 cm3 
of NaOH (1 mol dm-3). The solution was stirred at room 
temperature for 2 hours and then 25% of TFA in volume 
was slowly added with vigorous stirring. The solution 
was stirred at room temperature for 2 hours after which 
the solvent was evaporated at reduced pressure. The 
residue was dissolved in water (20 cm3) and extracted 
with ethyl acetate (5 times 10 cm3). The organic fractions 
were collected and washed with brine (20 cm3), dried 
with MgSO4 and the solvent evaporated at reduced 
pressure to give compound 9b (0.061 g, 40.8%) as a 
greenish oil. 1H NMR (400 MHz, CD3OCD3): δ = 6.94 
(d, J = 8.0 Hz, 1H, ArH), 7.33-7.41 (m, 3H, ArH + 
CH), 7.48-7.52 (m, 2H, ArH), 7.56-7.58 (m, 1H, ArH), 
7.69 (d, J = 7.2 Hz, 2H, ArH) ppm. 13C NMR (100.6 
MHz, CD3OCD3): δ = 115.59 (CH), 115.94 (CH), 120.99 
(CH), 126.73 (C), 127.65 (C), 129.30 (2CH), 129.90 
(CH), 130.65 (2CH), 133.27 (CH), 135.22 (C), 145.65 
(C), 149.55 (C), 166.54 (C=O), 166.84 (C=O) ppm. m/z 
(HRESI-MS) 300.08604, ([M + H]+, C16H14NO5, 
requires 300.08720). 
4.2.6.2. Synthesis of p-coumaroyl-Z-Phe-OH, (9e) The 
procedure described above for the synthesis of 7b was 
followed with 5e (0.341 g, 1.000 mmol) to give 
compound 7e (0.221 g, 52.1%) as a light white solid. 
M.p. 153.0-154.0 °C. 1H NMR (400 MHz, CDCl3): δ = 
1.57 (s, 9H, CH3 Boc), 3.87 (s, 3H, OCH3), 6.50 (d, J = 
15.6 Hz, 1H, Ar-CH=CH-), 7.20 (d, J = 8.4 Hz, 2H, 
ArH), 7.33-7.39 (m, 3H, ArH), 7.44-7.53 (m, 5H, ArH + 
CH), 7.66 (d, J = 15.6 Hz, 1H, Ar-CH=CH-) ppm. 13C 
NMR (100.6 MHz, CDCl3): δ = 27.58 [C(CH3)3], 52.80 
(CO2CH3), 83.95 [OC(CH3)3], 119.55 (CH), 121.70 
(2CH), 123.98 (C), 128.62 (CH), 128.89 (CH), 129.13 
(2CH), 129.39 (CH), 129.51 (C), 129.76 (CH), 130.36 
(CH), 131.88 (CH), 132.03 (C), 133.83 (C), 142.21 
(CH), 151.41 (C=O), 152.31 (C=O), 165.78 (C=O) ppm. 
m/z (HRESI-MS) 424.17479, ([M + H]+, C24H26NO6, 
requires 424.17601). Compound 7e (0.212 g, 0.500 
mmol) was reacted following the procedure described 
above for the synthesis of 9b to give 9e (0.086 g, 55.9%) 
as a light brown solid. M.p. 177.0-178.0 °C. 1H NMR 
(400 MHz, CD3OCD3): δ = 6.81 (d, J = 15.6 Hz, 1H, Ar-
CH=CH-), 6.93 (d, J = 8.4 Hz, 2H, ArH), 7.36-7.44 (m, 
4H, ArH + CH), 7.52 (d, J = 8.4 Hz, 2H, ArH), 7.58 (d, 
J = 15.6 Hz, 1H, Ar-CH=CH-), 7.67 (d, J = 7.2 Hz, 2H, 
ArH), 8.78 (br. s, 1H, NH)   ppm. 13C NMR (100.6 MHz, 
CD3OCD3): δ = 116.58 (2CH), 118.32 (CH), 127.34 (C), 
127.41 (C), 129.29 (2CH), 129.82 (CH), 130.45 (CH), 
130.68 (2CH), 131.44 (CH), 132.01 (CH), 135.23 (C), 
142.18 (CH), 160.20 (C=O), 166.91 (C=O) ppm. m/z 
(HRESI-MS) 310.10703, ([M + H]+, C18H16NO4, 
requires 310.10793). 
4.2.6.3. Synthesis of caffeoyl-Z-Phe-OH, (9f) The 
procedure described above for the synthesis of 7b was 
followed with 5f (0.536 g, 1.500 mmol) to give 7f (0.382 
g, 47.2%). Compound 7f (0.270 g, 0.500 mmol) was 
reacted following the procedure described above for the 
synthesis of 9b to give 9f (0.103 g, 63.2%) as a light 
green oil. 1H NMR (400 MHz, CD3OCD3): δ = 6.76 (d, J 
= 15.6 Hz, 1H, Ar-CH=CH-), 6.89 (d, J = 8.0 Hz, 1H, 
ArH), 7.03 (d, J = 8.0 Hz, 1H, ArH), 7.16 (s, 1H, ArH), 
7.34-7.43 (m, 4H, ArH), 7.53 (d, J = 15.6 Hz, 1H, Ar-
CH=CH-), 7.67 (d, J = 7.2 Hz, 2H, ArH), 8.80 (br. s, 1H, 
NH)  ppm. 13C NMR (100.6 MHz, CD3OCD3): δ = 
114.94 (CH), 116.28 (CH), 118.38 (CH), 122.03 (CH), 
127.27 (C), 128.13 (C), 129.32 (2CH), 129.90 (CH), 
130.70 (2CH), 132.24 (CH), 135.14 (C), 142.65 (CH), 
146.11 (C), 148.10 (C), 165.83 (C=O), 166.84 (C=O) 
ppm. m/z (HRESI-MS) 326.10215, ([M + H]+, 
C18H16NO5, requires 326.10285). 
4.2.6.4. Synthesis of hydrocaffeoyl-Z-Phe-OH, (9g) The 
procedure described above for the synthesis of 7b was 
followed with 5g (0.359 g, 1.000 mmol) to give 
compound 7g (0.294 g, 54.3%) as a white solid. M.p. 
156.0-157.0 °C. 1H NMR (400 MHz, CDCl3): δ = 1.55 
(s, 18H, CH3 Boc), 2.63-2.65 (m, 2H, CH2), 2.99-3.00 
(m, 2H, CH2), 3.84 (s, 3H, OCH3), 6.98 (br. s, 1H, ArH), 
7.08-7.18 (m, 3H, ArH + CH), 7.33-7.37 (m, 5H, ArH) 
ppm. 13C NMR (100.6 MHz, CDCl3): δ = 27.62 
[2C(CH3)3], 30.27 (CH2), 30.90 (CH2), 52.69 (CO2CH3), 
83.66 [OC(CH3)3], 83.68 [OC(CH3)3], 122.94 (2CH), 
123.02 (2CH), 124.14 (C), 126.32 (CH), 128.63 (CH), 
129.52 (2CH), 132.14 (CH), 133.64 (C), 139.29 (C), 
140.89 (C), 142.35 (C), 150.77 (C=O), 150.84 (C=O), 
165.62 (C=O), 170.29 (C=O) ppm. m/z (HRESI-MS) 
542.23866, ([M + H]+, C29H36NO9, requires 542.23901). 
Compound 7g (0.288 g, 0.532 mmol) was reacted 
following the procedure described above for the 
synthesis of 9b to give 9g (0.086 g, 33.6%) as a light 
green oil. 1H NMR (400 MHz, CD3OCD3): δ = 2.69 (t, J 
= 7.2 Hz, 2H, CH2), 2.87 (t, J = 7.2 Hz, 2H, CH2), 6.63 
(d, J = 7.2 Hz, 1H, ArH), 6.77 (d, J = 7.2 Hz, 1H, ArH), 
6.80 (s, 1H, CH), 7.33-7.38 (m, 4H, ArH), 7.50-7.56 
(m, 2H, ArH) ppm. 13C NMR (100.6 MHz, CD3OCD3): 
δ = 38.62 (2CH2), 115.94 (CH), 116.12 (CH), 120.43 
(CH), 127.27 (C), 129.30 (2CH), 129.81 (CH), 130.64 
(2CH), 132.41 (CH), 133.75 (C), 134.83 (C), 144.01 (C), 
145.62 (C), 166.88 (C=O), 172.47 (C=O) ppm. m/z 
(HRESI-MS) 328.11742, ([M + H]+, C18H18NO5, 
requires 328.11850). 
 
 
Acknowledgments  
 
This work received financial support from the Foundation 
for Science and Technology (FCT, Portugal), through projects 
UID/QUI/00686/2013,  UID/QUI/00686/2016 (CQUM) and 
UID/QUI/50006/2013–POCI-01-0145-FEDER-007265, co-
financed by European Union (FEDER under the Partnership 
Agreement PT2020), and from Norte Portugal Regional 
Operational Programme (NORTE 2020), under the 
PORTUGAL 2020 Partnership Agreement, through the 
  
13 
European Regional Development Fund (ERDF) (project 
NORTE-01-0145-FEDER- 24). 
 
Conflict of Interest: the authors declare that they have no 
conflict of interest.  
This article does not contain any studies with human 
participants or animals performed by any of the authors. 
 
References 
1. Wei Q-Y, Jiang H, Zhang J-X, Guo P-F, Wang H. Med. Chem. 
Res. 2012;21:1905–1911. 
2.  Kwak S-Y, Lee S, Yang JK, Lee Y-S. Food Chem. 
2012;130:847–852. 
3.  Seo H-S, Kwak S-Y, Lee Y-S. Bioorg. Med. Chem. Lett. 
2010;20:4266–4272. 
4. Kwak S-Y, Seo H-S, Lee Y-S. J. Pept. Sci. 2009;15:634–641. 
5.  Son S, Lewis BA. J. Agric. Food Chem. 2002;50:468–472. 
6. De Baltas P, Bedos-Belval F. Curr. Med. Chem. 2011;18:1672–
1703. 
7. Wei Q-Y, Jiang H, Zhang J-X, Zhang C, Guo P-F. Asian J. 
Chem. 2012;24:2383–2388. 
8. Narasimhan B, Belsare D, Pharande D, Mourya V, Dhake A. 
Eur. J. Med. Chem. 2004;39:827–834. 
9. Fu J, Cheng K, Zhang ZM, Fang RQ, Zhu HL. Eur. J. Med. 
Chem. 2010;45:2638–2643. 
10.  Chochkova MG, Chorbadzhiyska EY, Ivanova GI, Najdenski H, 
Ninova M, Milkova T. Nat. Prod. J. 2012;2:50–54. 
11. Georgiev L, Chochkova M, Ivanova G, Najdenski H, Ninova M, 
Milkova T. Riv. Ital. Sost. Grasse 2012;89:91–102. 
12. Heijnen CG, Haenen GR, Vekemans JA, Bast A. Environ. 
Toxicol. Pharmacol. 2001;10:199–206. 
13. Negrel J, Javelle F, Paynot M. J. Plant Physiol. 1993;142:518–
524. 
14. Peipp H, Maier W, Schmidt J, Wray V, Strac D. Phytochemistry 
1997;44:581–587. 
15. Fink W, Liefland M, Mendgen K. Physiol. Mol. Plant Pathol. 
1990;37:309–321. 
16. Negrel J, Lofty S, Javelle F. J. Plant Physiol. 1995;146:318–
325. 
17. Lee S, Han J-M, Kim H, Kim E, Jeong T-S, Lee WS, Cho K-H. 
Bioorg. Med. Chem. Lett. 2004;14:4677–4681. 
18. Spasova M, Kortenska-Kancheva V, Totseva I, Ivanova G, 
Georgiev L, Milkova T. J. Peptide Sci. 2006;12.369–375. 
19.  Georgiev L, Chochkova M, Totseva I, Seizova K, Marinova E, 
Ivanova G, Ninova M, Najdenski H, Milkova T. Med. Chem. 
Res. 2013;22:4173–4182. 
20.  Milde J, Elstner EF, Grassmann J. Mol. Nutr. Food Res. 
2007;51:956-961. 
21.  Milde J, Elstner EF, Grassmann J. Phytomedicine 2004;11:105-
113. 
22.  Shi J, Kakuda Y. Herbs: Challenges Chem. Biol. 2006;925:254-
264. 
23. Gonzalez-Perez O, Gonzalez-Castaneda RE. Nutr. Res. 
2006;26:1-5. 
24.  Yogeeta SK, Gnanapragasam A, Kumar SS, Subhashini R, 
Sathivel A, Devaki T. Mol. Cell. Biochem. 2006;283:139-146. 
25.  Trombino S, Serini S, Di Nicuolo F, Celleno L, Andò S, Picci N, 
Calviello G, Palozza P. J. Agric. Food Chem. 2004;52:2411-
2420. 
26.  Cirico TL, Omaye S. Food Chem. Toxicol. 2006;44:510-516. 
27.  Yamashita N, Murata M, Inoue S, Burkitt MJ, Milne L, 
Kawanishi S. Chem. Res. Toxicol. 1998;11:855-862. 
28.  Flueraru M, Chichirau A, Chepelev LL, Willmore WG, Durst T, 
Charron M, Barclay LRC, Wright JS. Free Radic. Biol. Med. 
2005;39:1368-1377. 
29.  Silvia V, Baldisserotto A, Scalambra E, Malisardi G, Durini E, 
Manfredini S. Eur. J. Med. Chem. 2012;50:383-392. 
30. Lee BP, Messersmith PB, Israelachvili JN, Waite JH. Annu. Rev. 
Mater. Res. 2011;41:99-132. 
31. Holten-Andersen N, Harrington MJ, Birkedal H, Lee BP, 
Messersmith PB, Lee KYC, Waite JH. Proc. Natl. Acad. Sci. 
USA 2011;108:2651-2655. 
32. Li L, Yan B, Yang J, Chen L, Zeng H. Adv. Mater. 
2015;27:1294–1299. 
33. Gilon C, Dechantsreiter MA, Burkhart F, Friedler A, Kessler H. 
Synthesis of N-alkylated peptides. In: Houben-Weyl: Methods of 
organic chemistry. Synthesis of peptides and peptidomimetics; 
Eds.: Goodman M, Felix A, Moroder L, Toniolo C. Thieme 
Verlag, Stuttgart, New York, E22c: 2003:215-271. 
34. Kotha S. Acc. Chem. Res. 2003;36:342-351. 
35. Rilatt I, Caggiano L, Jackson RFW. Synlett 2005:2701-2719 
36. Dawid S. Amino Acids, 2015;47:1–17. 
37. Gupta M, Chauhan VS. Biopolymers, 2011;95:161–173.  
38. Rudresh,  Ramakumar S, Ramagopal UA, Inai Y, Goel S, 
Sahal D, Chauhan VS. Structure, 2004;12:389-396. 
39. Bierbaum G, Gotz F, Peschel A, Kupke T, VandeKamp M, Sahl 
HG. Antonie Van Leeuwenhoek 1996;69:119–127. 
40.  Dunn AD, Corsi CM, Myers HE, Dunn JT. J. Biol. Chem. 
1998;273:25223–25229. 
41.  Paik SH, Chakicherla A, Hansen JN. J. Biol. Chem. 
1998;73:23134–23142. 
42.  Ghoshal AK, Rushmore TH, Buc-Calderon P, Roberfroid M, 
Farber E. Free Radic. Biol. Med. 1990;8:3–7. 
43. Buc-Calderon P, Sipe Jr HJ, Flitter W, Mason RP, Roberfroid 
M. Chem. Biol. Interact. 1990;73:77–88. 
44.  Suzen S, Gurkok, G, Coban T. J. Enzyme Inh. Med. Chem. 
2006;21:179-185. 
45.  Stadtman ER,  Levine RL. Amino acids 2003;25:207–218. 
46. Wagner AF, Demand J, Schilling G, Pils T, Knappe J. Biochem. 
Biophys. Res. Commun. 1999;254:306–310. 
47.  Genard S, Galey JB, Hocquaux M. 1999, United States Patent 
5871755. 
48.  Ferreira PMT, Monteiro LS, Coban T, Suzen S. J. Enzyme Inh. 
Med. Chem. 2009;24:967-971. 
49.  Vilaça H, Pereira G, Castro TG, Hermenegildo BF, Shi J, 
Faria TQ, Micaêlo N, Brito RMM, Xu B, Castanheira EMS, 
Martins JA, Ferreira PMT. J. Mater. Chem. B, 2015;3:6355-636. 
50.  Vilaça H, Hortelão ACL, Castanheira EMS, Queiroz M-JRP, 
Hilliou L, Hamley I, Martins JA, Ferreira PMT. 
Biomacromolecules, 2015;16:3562-3673. 
51. Ferreira PMT, Maia HLS, Monteiro LS, Sacramento J. J. Chem. 
Soc., Perkin Trans. 1 1999:3697-3703. 
52. Ferreira PMT, Monteiro LSM, Pereira G, Silva L, Ribeiro L, 
Sacramento J. Eur. J. Org. Chem. 2007.5934-5949. 
53. Pereira DM, Correia-da-Silva G, Valentão P, Teixeira N, 
Andrade PB. Combinatorial Chemistry and High Throughput 
Screening 2014;17:450-457. 
54. Grehn L, Gunnarsson K, Ragnarsson U. Acta Chem. Scand. Ser. 
B, 1987;41:18-23. 
55. Lopez-Ayllon BD, Moncho-Amor V, Abarrategi A, Cáceres II, 
Castro-Carpeño J, Belda-Iniesta C, Perona R, Sastre L. Cancer 
Medicine 2014:1099-1111. 
 
